Walgreens Boots Alliance, Inc.

WBA

US9314271084

Drug Retailers

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
17.7 ^USD	+0.57%		-2.96%	-32.21%

Apr. 26	CVS Omnicare staff in Las Vegas vote to join new union	RE
Apr. 26	Morgan Stanley Adjusts Price Target on Walgreens Boots Alliance to $16 From $20	MT

WALGREENS BOOTS ALLIANCE : UBS gives a Neutral rating

January 04, 2024 at 11:33 am EST

Initially Neutral on the company, UBS's analyst Kevin Caliendo maintained his recommendation. The target price remains set at USD 25.

Latest news about Walgreens Boots Alliance, Inc.

CVS Omnicare staff in Las Vegas vote to join new union	Apr. 26	RE
Morgan Stanley Adjusts Price Target on Walgreens Boots Alliance to $16 From $20	Apr. 26	MT
Walgreens Boots Alliance Keeps Quarterly Dividend at $0.25 Per Share, Payable June 12 to Shareholders of Record May 21	Apr. 25	MT
Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024	Apr. 25	CI
Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business	Apr. 24	CI
DoorDash Partners With WalGreens to Offer Payment Option for SNAP Customers in US	Apr. 24	MT
DoorDash and Walgreens Launch Unprecedented Access for SNAP Customers	Apr. 24	CI
Truist Securities Adjusts Price Target on Walgreens Boots Alliance to $20 From $25	Apr. 15	MT
RBC Capital Cuts Walgreens Boots Alliance's Price Target to $22 From $26, Sector Perform Rating Kept	Apr. 12	MT
UBS Cuts Walgreens Boots Alliance's Price Target to $22 From $25, Maintains Neutral Rating	Apr. 03	MT
Economic Data Leave Equity Markets Mixed; Yields Surge	Apr. 01	MT
Economic Data Leave Equity Markets Mixed; Yields Surge	Apr. 01	MT
News Highlights : Top Company News of the Day - Thursday at 7 PM ET	Mar. 28	DJ
S&P closes higher to secure strongest Q1 since 2019	Mar. 28	RE
News Highlights : Top Company News of the Day - Thursday at 5 PM ET	Mar. 28	DJ
Dow, S&P 500 Close at Record Highs as Traders Parse Macro Data	Mar. 28	MT
Dow, S&P 500 Close at Record Highs as Traders Parse Macro Data	Mar. 28	MT
US Equity Markets Mixed Thursday Following Upwardly Revised Q4 Economic Growth	Mar. 28	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 28	MT
Walgreens CEO on Narrowed Forecast, Shoppers Cutting Back Spending	Mar. 28	MT
Walgreens Boots Alliance's Fiscal Q2 Non-GAAP Earnings, Sales Rise; Fiscal 2024 Adjusted EPS Outlook Revised	Mar. 28	MT
News Highlights : Top Company News of the Day - Thursday at 3 PM ET	Mar. 28	DJ
Equities poised to wrap up strong quarter on quiet note	Mar. 28	RE
Economic Data Leave Equity Markets Mixed Intraday	Mar. 28	MT
Top Midday Stories: Bankman-Fried Gets 25-Year Prison Sentence; Home Depot Acquiring SRS Distribution; Walgreens Lowers FY 2024 Outlook; Analyst Says Short MicroStrategy; Canadian School Boards Sue Social Media Platforms; Eli Lilly Weight-Loss Drug Facing Shortage	Mar. 28	MT

Chart Walgreens Boots Alliance, Inc.

Duration

Period

More charts

Walgreens Boots Alliance, Inc. specializes in the distribution of pharmaceutical products. Net sales break down by activity as follows: - retail distribution (87.2%): selling prescription drugs, OTC medicines, beauty and cosmetic products, etc. in the United States (90.9% of net sales) and internationally (9.1%). At the end of August 2023, the activity is carried out through 13,532 outlets (of which 8,706 located in the United States, Puerto Rico and the US Virgin Islands), and through the Internet; - wholesale distribution (8.1%). The remaining sales (4.7%) are from the healthcare Net sales break down geographically as follows: the United States (84%), Germany (8.1%), the United Kingdom (6.5%) and other (1.4%).

Sector

Drug Retailers

Calendar

2024-06-26 - Q3 2024 Earnings Release (Projected)

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Walgreens CEO on Narrowed Forecast, Shoppers Cutting Back Spending

March 28, 2024 at 03:59 pm EDT

Walgreens Boots Alliance, Inc. first light at the end of the tunnel?

November 27, 2023 at 10:22 am EST

More Strategies

Ratings for Walgreens Boots Alliance, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

17.7 USD

Average target price

23.1 USD

Spread / Average Target

+30.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
WALGREENS BOOTS ALLIANCE, INC.	-32.21%	15.27B
JD HEALTH INTERNATIONAL INC.	-31.97%	10.84B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-30.42%	6.06B
YIFENG PHARMACY CHAIN CO., LTD.	+8.14%	6.04B
MATSUKIYOCOCOKARA & CO.	-11.41%	5.86B
NAHDI MEDICAL COMPANY	-0.88%	4.71B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+52.19%	4.29B
CLICKS GROUP LIMITED	-12.31%	3.61B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-14.86%	3.33B
WELCIA HOLDINGS CO., LTD.	-6.93%	3.01B

Other Drug Retailers

Walgreens Boots Alliance, Inc.

Equities

WBA

US9314271084

Drug Retailers

WALGREENS BOOTS ALLIANCE : UBS gives a Neutral rating

EPS Revisions